8-K filing — Quince Therapeutics, Inc. (QNCX)
Filed: 2026-08-17 AccNo: 0001193125-26-353141 Size: 202 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 10:59 AM
- Checked
- Aug 18, 2026, 10:59 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share
Read original at benzingaQuince Therapeutics Says Brigette Roberts Conditionally Appointed As CEO; John Militello Conditionally Appointed As CFO
-SEC Filing
Read original at benzinga